Clinical trial NCT03292653: Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
Official title: An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients Hospitalized With Worsening Heart Failure
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Cardiac Failure Aggravated
Lead sponsor: Lexicon Pharmaceuticals
Sponsor class: INDUSTRY
Collaborators: name: Sanofi
First posted: 2017-09-25
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary Objectives:

* Assess the safety and tolerability of sotagliflozin in hemodynamically stable participants with worsening of heart failure, compared to placebo.
* Estimate the effects of sotagliflozin on plasma volume changes in hemodynamically stable participants with worsening of heart failure, compared to placebo.

Secondary Objectives:

* Explore the effect of sotagliflozin on erythropoiesis, as assessed by changes in plasma erythropoietin levels, in hemodynamically stable participants with worsening of heart failure, compared to placebo.
* Explore the effect of sotagliflozin on changes in plasma N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels, in hemodynamically stable participants with worsening of heart failure, compared to placebo.

Detailed description: The total study duration will be approximately 27-40 days, including a screening period of 1-10 days, a treatment period of 14 days, and a follow-up period of 14±2 days.

Eligibility criteria: Inclusion criteria:

* Written informed consent.
* 18 years of age or older.
* Participants admitted to the hospital or had urgent visit to emergency department or heart failure unit/clinic or infusion center for Congestive Heart Failure (CHF), defined by:
* Presence of ≥2 of the following clinical signs and symptoms of congestion: jugular venous distension, pitting edema in lower extremities greater than trace, dyspnea, rales heard on auscultation, radiographic pulmonary congestion, weight gain above historical dry weight of at least 5 pounds (lbs) (2.27 Kilograms (kg)).
* Requiring treatment with intravenous (IV) diuretics.
* Estimated glomerular filtration rate (eGFR) ≥30 milliliter per minute (mL/min)/1.73 square meter (m\^2) at the screening or randomization visit by the 4 variable Modification of Diet in Renal Disease (MDRD) equation.
* Female participants must use a double contraception method during the study including a highly effective method of birth control, except if she has undergone sterilization at least 3 months earlier or is postmenopausal.
* Male participants, unless vasectomized and confirmed sterile by sperm analysis, must use condoms during the study and refrain from donating sperm up to 90 days after the day of last dose. If the participant has a female partner of childbearing potential, the participant must wear a condom and female partner must use at least 1 highly effective method of birth control during the study treatment period and the Follow-up period.
* Transitioning from IV to oral diuretics, and oral diuretic treatment has been prescribed or administered.
* Hemodynamically stable, defined as systolic blood pressure (SBP) \>100 millimeters of mercury (mmHg) with no requirement for IV inotropes or IV vasodilators.

Exclusion criteria :

* History of Type 1 diabetes mellitus.
* Appears unlikely or unable to participate in the required study procedures, as assessed by the study Investigator, study coordinator, or designee (ex: clinically-significant psychiatric, addictive, or neurological disease), or sectioned due to an official or court order.
* Current admission or visit for Worsening Heart Failure (HF) that is clearly and primarily triggered by causes such as tachyarrhythmia (example: sustained ventricular tachycardia, or atrial fibrillation/flutter with sustained ventricular response \> 130 beats per minute), acute coronary syndrome, pulmonary embolism, cerebrovascular accident, heart valve disorders (such as severe aortic stenosis), as determined by the Investigator.
* Clinically significant myocardial infarction (MI) within past 1 month as determined by Investigator and with objective evidence from ECG, and/or cardiac imaging and/or coronary angiography. Small isolated elevations in troponin that often accompany HF hospitalization are not an exclusion, nor are clinically significant MIs that have been revascularized without complications.
* Participants who recently had or scheduled to have cardiac interventions may be eligible if:
* Stable 48 hours post procedure.
* Have diuretic treatment planned for the duration of treatment in this study.
* Current use of or recent suspension of digoxin therapy with high levels of digoxin (level should be obtained and must be \<1.2 nanograms per milliliter (ng/mL) at screening.
* History of heart or kidney transplant.
* Diagnosis of hypertrophic obstructive cardiomyopathy.
* End-stage HF defined as requiring left ventricular assist device insertion, intra-aortic balloon placement (IABP), or any type of mechanical support during the study period.
* Pregnancy (demonstrated by serum pregnancy test at screening), breast-feeding, or inability or refusal to undergo pregnancy testing.
* Use of any investigational drug(s) or prohibited therapy or sodium-glucose co-transporter 2 (SGLT2) 5 half-lives prior to screening.
* Participants with moderate or severe respiratory, hepatic, neurological, psychiatric, active malignant tumor or other major systemic disease (including any diseases with evidence of malabsorption), making implementation of the protocol and/or the interpretation of the study results difficult.
* Known allergies, hypersensitivity, or intolerance to sotagliflozin or any inactive component of sotagliflozin or placebo (ie, microcrystalline cellulose, croscarmellose sodium \[disintegrant\], talc, silicon dioxide, and magnesium stearate \[non-bovine\]), unless the reaction is deemed irrelevant to the study by the PI.
* Laboratory findings at the Screening Visit:
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 times the upper limit of the normal laboratory range (ULN) (1 repeat lab allowed).
* Total bilirubin \>1.7 times the ULN (except in case of Gilbert's syndrome) (1 repeat lab allowed).
* Amylase and/or lipase \>3 times the ULN (1 repeat lab allowed).
* Participants with a severe or persistent in spite of optimal treatment genitourinary tract infection at time of randomization.
* Participant is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
* History of diabetic ketoacidosis or non-ketotic hyperosmolar coma within 3 months prior to the screening visit.
* Lower extremity diabetic complications (such as skin ulcers, infection, osteomyelitis and gangrene) identified during the Screening period, and still requiring treatment at randomization.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Primary outcomes:
measure: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths
timeFrame: Baseline up to Day 14
measure: Change From Baseline in Hemoconcentration as Assessed by Changes in Albumin to Day 14
timeFrame: Baseline to Day 14
measure: Change From Baseline in Hemoconcentration as Assessed by Changes in Hematocrit to Day 14
timeFrame: Baseline to Day 14
measure: Change From Baseline in Hemoconcentration as Assessed by Changes in Hemoglobin to Day 14
timeFrame: Baseline to Day 14
measure: Change From Baseline in Hemoconcentration as Assessed by Changes in Total Protein to Day 14
timeFrame: Baseline to Day 14
measure: Changes From Baseline in Plasma Volume to Day 14
timeFrame: Baseline to 14 Days
Secondary outcomes:
measure: Change From Baseline in Erythropoietin to Day 14
timeFrame: Baseline to Day 14
measure: Change From Baseline in N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) to Day 14
timeFrame: Baseline to Day 14
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Investigational Site Number 8400005
state: California
city: New Haven
country: United States
facility: Investigational Site Number 8400001
state: Connecticut
city: Rochester
country: United States
facility: Investigational Site Number 8400007
state: Minnesota
city: Cleveland
country: United States
facility: Investigational Site Number 8400002
state: Ohio
city: Toronto
country: Canada
facility: Investigational Site Number 1240001
city: Groningen
country: Netherlands
facility: Investigational Site Number 5280001
Study officials:
affiliation: Lexicon Pharmaceuticals, Inc.
name: Suman Wason, MD
role: STUDY_DIRECTOR
References: